[go: up one dir, main page]

BR9702328A - Derivados de 4-aralquilaminopirimidina bicíclicos como inibidores de quinase tirosina - Google Patents

Derivados de 4-aralquilaminopirimidina bicíclicos como inibidores de quinase tirosina

Info

Publication number
BR9702328A
BR9702328A BR9702328A BR9702328A BR9702328A BR 9702328 A BR9702328 A BR 9702328A BR 9702328 A BR9702328 A BR 9702328A BR 9702328 A BR9702328 A BR 9702328A BR 9702328 A BR9702328 A BR 9702328A
Authority
BR
Brazil
Prior art keywords
bicyclic
tyrosine kinase
kinase inhibitors
aralkylaminopyrimidine
derivatives
Prior art date
Application number
BR9702328A
Other languages
English (en)
Inventor
Maria Gabriella Brasca
Franco Buzzetti
Antonio Longo
Dario Ballinari
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of BR9702328A publication Critical patent/BR9702328A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
BR9702328A 1996-06-21 1997-06-03 Derivados de 4-aralquilaminopirimidina bicíclicos como inibidores de quinase tirosina BR9702328A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613021.6A GB9613021D0 (en) 1996-06-21 1996-06-21 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
PCT/EP1997/002965 WO1997049689A1 (en) 1996-06-21 1997-06-03 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BR9702328A true BR9702328A (pt) 1999-07-20

Family

ID=10795666

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9702328A BR9702328A (pt) 1996-06-21 1997-06-03 Derivados de 4-aralquilaminopirimidina bicíclicos como inibidores de quinase tirosina

Country Status (20)

Country Link
US (1) US6057326A (pt)
EP (1) EP0853616B1 (pt)
JP (1) JPH11511761A (pt)
KR (1) KR19990043993A (pt)
CN (1) CN1198158A (pt)
AR (1) AR008614A1 (pt)
AT (1) ATE205836T1 (pt)
AU (1) AU3094197A (pt)
BR (1) BR9702328A (pt)
CA (1) CA2228492C (pt)
DE (1) DE69706823T2 (pt)
EA (1) EA199800215A1 (pt)
ES (1) ES2165061T3 (pt)
GB (1) GB9613021D0 (pt)
HU (1) HUP9902026A3 (pt)
IL (1) IL123124A0 (pt)
NO (1) NO980718L (pt)
PL (1) PL325122A1 (pt)
WO (1) WO1997049689A1 (pt)
ZA (1) ZA975380B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6347480B1 (en) * 1997-07-07 2002-02-19 Southpac Trust International, Inc. Method for wrapping a floral grouping with a sheet of material constructed of paper and having printed and embossed patterns thereon
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
PL205557B1 (pl) * 1999-02-10 2010-05-31 Astrazeneca Ab Pochodne indolu
AU1071301A (en) * 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
AU769222B2 (en) 1999-11-05 2004-01-22 Genzyme Corporation Quinazoline derivatives as VEGF inhibitors
PT1274692E (pt) 2000-04-07 2006-11-30 Astrazeneca Ab Compostos de quinazolina
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
JP2007502776A (ja) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｒｔｋ阻害剤としての６−置換アニリノプリン類
ES2554330T3 (es) * 2004-02-19 2015-12-18 Rexahn Pharmaceuticals, Inc. Derivados de quinazolina y uso terapéutico de los mismos
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
EP1863792B1 (en) * 2005-03-28 2009-01-21 Brystol-Myers Squibb Company Atp competitive kinase inhibitors
TWI385174B (zh) * 2008-11-10 2013-02-11 Nat Health Research Institutes 作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
CA2822070C (en) * 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
JP2022527025A (ja) * 2019-04-03 2022-05-27 ミトキニン インコーポレイテッド 神経変性疾患及びミトコンドリア病の治療のための組成物及びその使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89028A0 (en) * 1988-01-29 1989-08-15 Lilly Co Eli Quinoline,quinazoline and cinnoline derivatives
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents
JP2762430B2 (ja) * 1991-01-18 1998-06-04 宇部興産株式会社 アラルキルアミノピリミジン類の製法
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH06172321A (ja) * 1992-10-08 1994-06-21 Agro Kanesho Co Ltd 置換アミノピリミジン誘導体、その製造法及びそれを有効成分とする有害生物駆除剤
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation

Also Published As

Publication number Publication date
CA2228492A1 (en) 1997-12-31
AU3094197A (en) 1998-01-14
KR19990043993A (ko) 1999-06-25
HUP9902026A2 (hu) 2000-04-28
EP0853616B1 (en) 2001-09-19
ATE205836T1 (de) 2001-10-15
NO980718L (no) 1998-04-08
DE69706823T2 (de) 2002-04-11
WO1997049689A1 (en) 1997-12-31
CN1198158A (zh) 1998-11-04
EA199800215A1 (ru) 1998-08-27
US6057326A (en) 2000-05-02
EP0853616A1 (en) 1998-07-22
PL325122A1 (en) 1998-07-06
HUP9902026A3 (en) 2000-07-28
MX9801408A (es) 1998-05-31
GB9613021D0 (en) 1996-08-28
DE69706823D1 (en) 2001-10-25
AR008614A1 (es) 2000-02-09
NO980718D0 (no) 1998-02-20
ZA975380B (en) 1998-01-05
ES2165061T3 (es) 2002-03-01
IL123124A0 (en) 1998-09-24
CA2228492C (en) 2007-05-08
JPH11511761A (ja) 1999-10-12

Similar Documents

Publication Publication Date Title
BR9702328A (pt) Derivados de 4-aralquilaminopirimidina bicíclicos como inibidores de quinase tirosina
PT1117659E (pt) Cianoquinolinas substituidas como inibidores de tirosina-quinases de proteinas
CY2008015I2 (el) Δικυκλικες ετepοαρωματικες ενωσεις σαν αναστολεις πρωτεϊνης κινασης τυροσινης
NO990124D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
NO990123D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
EP1161433A4 (en) TYROSINE KINASE INHIBITORS
PT912559E (pt) Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
NO992524D0 (no) Konsenserte bicykliske pyrimidin-derivater
DZ3223A1 (fr) Inhibiteurs de tyrosine kinases
CY2014034I2 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
NO970501D0 (no) Substituerte kinazolinderivater
PT946512E (pt) Derivados de 6-fenilpiridil-2-amina uteis como inibidores de nos
HUP9901155A3 (en) Quinazoline derivatives as vegf inhibitors
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
MX9204425A (es) Derivados de quinazolina como inhibidores de la acetilcolinesterasa.
PT858452E (pt) Derivado tiazol como inibidor da proteina-quinase c
PT922034E (pt) Derivados tetra-hidroquinolina como antagonistas de eaa
BR9611504A (pt) Derivados de quinolina como inibidores de fosfodiesterase do tipo iv
PT1023268E (pt) Isoquinolinas como inibidores de uroquinase
FI955661A7 (fi) Substituoidut beta-aryyli- ja beta-heteroaryyli-alfa-syanoakryyliamidi johdannaiset tyrosiinikinaasi-inhibiittoreina
GB9600997D0 (en) N-indolinyl-pyridopyrimidines as tyrosine kinase inhibitors

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]